2 private satellites undock after pioneering life-extension mission
Two commercial satellites have completed an undocking maneuver high above Earth, signaling the successful end to a pioneering spacecraft life-extension mission.
The Mission Extension Vehicle-1 (MEV-1), developed by Northrop Grumman Corporation's Space Logistics LLC, docked with Intelsat's IS-901 communications satellite in 2020 in a graveyard orbit, a few hundred miles above geosynchronous orbit (GEO), an orbital belt 22,236 miles (35,786 kilometers) above Earth.
MEV-1, which launched atop a Russian Proton rocket in October 2019 from Baikonur Cosmodrome in Kazakhstan, then brought IS-901 back to GEO and allowed it to restart its operations. But now, after extending the life of IS-901 for five years, the mission has come to an end.
IS-901 has been taken back into the GEO graveyard — where decommissioned satellites are positioned to remove them safely from the active GEO belt — by MEV-1. There, the two spacecraft undocked. Just as the 2020 rendezvous was the first docking between commercial spacecraft in GEO, this marks the first such commercial undocking.
Related: Watch Northrop Grumman's MEV-1 dock with Intelsat 901!
This is not the end for MEV-1, however, as the spacecraft is currently relocating to the next servicing mission, according to Northrop Grumman. This is all part of the company's plans to provide life-extension services for satellites in GEO.
"The first-of-its kind technology that extended a satellite's life is paving the way for an entire infrastructure of future on-orbit satellite servicing missions for a variety of customers," Rob Hauge, president of Northrop Grumman Space Logistics, said in an April 9 statement. "We are continuing to invest in next-generation capabilities to deliver the most technologically advanced servicing capabilities to support and maintain new and existing space-based assets."
MEV-1 is not the only player in the satellite life-extension game. Northrop Grumman Space Logistics' follow-on spacecraft, MEV-2, is currently docked to Intelsat 10-02 and will continue providing life-extension services for an additional four years.
— Private Astroscale probe will refuel Space Force satellites high above Earth on landmark 2026 mission
— Ailing Intelsat satellite begins new life in orbit after historic servicing mission success
— NASA cancels multibillion-dollar on-orbit satellite servicing mission
The U.S. Space Force also recently tapped Northrop Grumman for the Elixir refueling payload program, which will "enable the Space Force to refine tactics and procedures for rendezvous and proximity operations, docking, refueling, and undocking of on-orbit vehicles," according to a different Northrop Grumman statement.
Meanwhile, Astroscale U.S. will attempt to refuel a pair of Space Force spacecraft in 2026, following an announcement at the 40th Space Symposium in Colorado Springs earlier this month. Elsewhere, China launched its own experimental refueling spacecraft, Shijian 25, in January this year.
Countries and companies are pursuing life extension and satellite-servicing capabilities for a range of uses and reasons, including reducing space debris, potential cost savings and enabling flexible and sustainable satellite operations.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
4 hours ago
- New York Post
How drugs like Ozempic can help treat asthma — even if you don't have diabetes
Asthma sufferers, get pumped! Managing asthma often requires a two-pronged approach — long-term medicines to prevent attacks and rescue strategies to stop attacks when they happen. It's important to avoid triggers and monitor breathing. New research out of the UK suggests that GLP-1 medications like Ozempic and Victoza may provide long-term asthma relief — in addition to shrinking waistlines. Advertisement 4 Asthma sufferers may benefit from GLP-1 drugs like Ozempic and Wegovy, a new study finds. Pixel-Shot – 'This study is a good reminder that GLP-1s shouldn't just be labeled as 'weight loss drugs,'' Dr. Michael Snyder, who was not involved in the new study, told The Post. 'They're part of a broader shift in medicine toward treating chronic diseases at the systems level.' Advertisement Researchers from the University of Aberdeen and the Observational and Pragmatic Research Institute studied over 10,000 obese, asthmatic patients taking GLP-1 drugs, comparing them to about 50,000 adults who had similar medical histories but were not taking GLP-1s. The GLP-1 users had fewer asthma attacks and symptoms after a year, though there wasn't much difference between that group and the asthma patients not on GLP-1 drugs. 4 GLP-1s often cause weight loss, which has been shown to reduce the severity of asthma. Other factors may also be at play. millaf – The researchers attributed this outcome to 'large numbers of missing data' due to disruptions in information collection during the COVID-19 pandemic. Advertisement Though the data was limited, the study authors noted that the GLP-1 group shed an average of 7.7 pounds while the other group lost an average of 2 pounds. It's unclear if the GLP-1 participants suffered side effects like nausea or vomiting. The results were published recently in the journal Advances in Therapy. This is not the first study to demonstrate that GLP-1 drugs can help asthma sufferers, particularly those with Type 2 diabetes and obesity. Advertisement Obesity is a well-known risk factor for asthma. One reason is that fat tissue can produce inflammatory substances that negatively affect the lungs and worsen asthma. GLP-1 drugs often cause weight loss because they mimic the GLP-1 hormone the body naturally produces after eating. Appetite decreases as users feel fuller for longer. The meds are prescribed to people with obesity and/or Type 2 diabetes. 4 Managing asthma often requires a two-pronged approach — long-term medicines to prevent attacks and rescue strategies to stop attacks when they happen. Pixel-Shot – Snyder, medical director of the Bariatric Surgery Center at Rose Medical Center in Denver and in-house obesity specialist at FuturHealth, suggests that these drugs could be useful for asthmatics who aren't obese or diabetic. 'These drugs appear to have anti-inflammatory effects, which is key since asthma is, at its core, an inflammatory disease,' Snyder said. 'They may also help calm airway hyperresponsiveness — in other words, making the lungs less reactive to common asthma triggers like allergens or pollution,' he added. 'And of course, the weight loss many patients experience can also improve lung function and reduce asthma severity, so it's likely a combination of these effects working together.' Snyder said more research is needed to confirm the effects in people who are not obese. Advertisement Dr. Thomas Kilkenny, director of the Institute of Sleep Medicine, Pulmonary & Critical Care at Northwell's Staten Island University Hospital, said the participants' better breathing is simply due to the weight loss. 'It has been shown multiple times in the past, and various studies show that weight loss alone improves asthma control,' Kilkenny told MedicalNewsToday. 4 Researchers have long been exploring uses for GLP-1 drugs beyond obesity and Type 2 diabetes. Fernanda – 'This study did not comment on whether the GLP-1 medication had a direct effect on the physiology of asthma control,' he added. Advertisement Since the first GLP-1 drug was approved 20 years ago to treat Type 2 diabetes, researchers have suggested that these meds can also relieve knee osteoarthritis pain, calm skin conditions, lower the odds of heart troubles and reduce dementia risk. 'Conditions like asthma, diabetes, sleep apnea, dementia and even cardiovascular disease don't exist in silos; they're deeply interconnected,' Snyder said. 'The fact that GLP-1s may impact all of them suggests we're entering a new era where the focus is not just on symptom management, but on rebalancing the underlying biology driving disease.'
Yahoo
7 hours ago
- Yahoo
CPI Aerostructures, Inc. (CVU) Secures Follow-On Orders Worth $2.4M for Welded Assemblies
CPI Aerostructures, Inc. (NYSEAMERICAN:CVU) is among the 10 Best Low Priced Defense Stocks to Buy Now. On July 30, the company announced that it was awarded follow-on orders worth $2.4 million from multiple customers to weld complex structural assemblies used on a U.S. military helicopter. Dorith Hakim, President and CEO of CPI Aerostructures, Inc. (NYSEAMERICAN:CVU), welcomed the order, saying he was proud of the company's rich history of providing components and assemblies for fixed and rotary wing aircraft for the U.S. military and allied forces. He further added that CPI Aerostructures, Inc. (NYSEAMERICAN:CVU)'s fusion welding capability was widely regarded across the industry and that the recent orders demonstrate the company's commitment to excellence in delivering fusion welded assemblies for its customers. CPI Aerostructures, Inc. (NYSEAMERICAN:CVU) manufactures structural parts for fixed-wing aircraft and helicopters in the commercial and defense markets. In April this year, the company completed the delivery of an ALMDS pod structure in support of Northrop Grumman's contract for a Korean program. While we acknowledge the potential of CVU as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Aerospace Stocks to Buy Now and 13 Best Global Stocks to Buy Right Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 hours ago
- Yahoo
Here Is What You Need To Know Before Investing In Momentus Inc. (MNTS)
Momentus Inc. (NASDAQ:MNTS) is among the 10 Best Low Priced Defense Stocks to Buy Now based on hedge fund sentiment. The commercial space company offers satellite buses and in-space infrastructure services, including hosted payloads, in-space transportation, and other in-orbit services. A close up of a satellite in space, showing the advanced technology of communications systems. It is also working on several space-related defense contracts. Last month, the firm announced signing a $1.86 million SBIR contract with SpaceWERX, the innovation wing of the U.S. Space Force, to support an in-space flight demonstration of a low-cost multi-spectral sensor suite for Rendezvous and Proximity Operations (RPO). It is scheduled for early next year. Earlier in the year, Momentus Inc. (NASDAQ:MNTS) was selected by the U.S. Air Force to demonstrate low-cost sensors for in-space Rendezvous and Proximity Operations (RPO). The company also recently shared that it had received around $1.2 million in payments since March 2025 for the successful execution of several milestones under the DARPA contract for the assembly of large structures in space. Momentus Inc. (NASDAQ:MNTS)'s share price has been pressured in 2025, with a year-to-date decline of over 85% due to various factors, including financial challenges and several delisting warnings and deficiency notices over the past year. While we acknowledge the potential of MNTS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Aerospace Stocks to Buy Now and 13 Best Global Stocks to Buy Right Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
